Good day, thank you for standing by. Welcome to the Outset Medical First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one-one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one-one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jim Mazzola, Head of Investor Relations. Good afternoon, everyone. Welcome to our first quarter 2023 earnings call. Here with me today are Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer. During the call, we will discuss our first quarter 2023 operational and financial results and host a question-and-answer session. We issued a news release after the close of market today and updated our investor presentation, both of which can be found on the investor relations pages of outsetmedical.com. This call is being recorded and will be archived in the investors section of our website. It is our intent that all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. These statements relate to expectations or predictions of future events, are based on our current estimates and various assumptions, and involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied. Outset assumes no obligation to update these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of Outset's public filings with the Securities and Exchange Commission, including our latest annual and quarterly reports. With that, I'll now turn the call over to Leslie. Thanks, Jim. Good afternoon, everyone, and thank you for joining us. We had a strong start to 2023, with revenue growing ahead of our original expectations and margins expanding for the eighth consecutive quarter, also ahead of our plan. The momentum we had exiting 2022 carried through the first quarter and positions us well for continued revenue growth and margin expansion through the remainder of the year. Specifically, Revenue for the first quarter was $33.5 million, representing approximately 10% growth year-over-year and approximately 5% growth sequentially. While we did see some of the capital equipment purchasing seasonality we had anticipated on our Q4 call, Tablo uptake remained strong. Our installed base grew in both the acute care and home markets, and we benefited from strong mix and pricing across the board. On the operational front, our ongoing cost down and efficiency initiatives continued to pay off, resulting in gross margin that expanded sequentially by another 3 percentage points. We maintain our conviction in the fundamentals of our business, supported by a healthy pipeline and backlog, with interest in and demand for Tablo strong and growing. Our success in the first quarter lays the groundwork for accelerating growth through the balance of 2023. As a result, we are raising the midpoint of our revenue guidance and also increasing our gross margin guidance today, both of which Nabeel will elaborate on shortly. First, I'd like to begin with a review of our results in the acute market during the first quarter, another consecutive quarter of strong growth. In short, our Q1 results came in better than expected. We were pleased with our ability to drive upside over our expectations. Our skilled US commercial team continued to deploy our proven land and expand strategy during the quarter, closing new sales agreements and expansion sales within existing accounts, and we continue to see customers make the decision to insource inpatient dialysis with Tablo. We're pleased to see this momentum with a growing number of providers recognizing the cost savings associated with insourcing initiatives and eager to move forward bringing Tablo in-house. We had a record number of consoles shipped to large regional IDNs, including a deployment of more than 50 Tablo consoles to a single IDN. Additionally, we added more than 30 new hospital sites to our roster during the first quarter, the largest quarterly growth in new sites since 2021. Our acute progress is a direct testament to the strong economic value proposition of Tablo. In any climate, direct measurable cost reduction is valuable to hospitals, but never more so than it is today. Because hospitals are not separately reimbursed for inpatient dialysis in most circumstances, it's a pure play cost center for them. Because inpatient dialysis ends up being provided as part of hundreds of different DRGs, the cost of dialysis can impact the hospital's procedural profitability broadly. Because Tablo directly lowers the hospital's dialysis cost by 50%-75% with a typically rapid payback period, we continue to see hospital administrators prioritize Tablo in their capital spending plans. Our Bridge Program continued to be a strong complementary offering for customers who are considering in-sourcing their dialysis service line. As we've discussed before, Bridge provides customers with the confidence to move forward by serving as a staffing backstop in case their own hiring takes longer than expected. As in Q4, we found in Q1 that most customers were able to hire on a timely basis and proceed with in-sourcing without needing to use Bridge. In situations where we have deployed it, we found that customers are able to staff their programs faster than they expected, which also enables us to operate the program cost efficiently. A good example is Deaconess Hospital in the Midwest. Deaconess operated a large outsourced dialysis program for more than 10 years. They were forced to bear the rising cost of their outsourced provider and accept lower service levels, their team decided to explore in-sourcing with Tablo. The Outset team and the Bridge Program, Deaconess was able to hire their own staff and stand up their in-house operation in 31 days. According to the program director, the hospital has observed a 99% clinical success rate during the first five months, dramatically lowered their costs and improved patient outcomes. These results are not unique to Deaconess. As we continue to expand our footprint in U.S. hospitals, we're finding these results are repeatable and sustainable. Another important element of our commercial strategy is to drive utilization across the install base. We were pleased to see positive trends in treatment volume during the quarter, in line with our expectations. We also saw ASPs rise both on consoles and consumables, which serves as strong validation of Tablo's clinical and economic value proposition versus our competitors. Our ASPs benefited again from better than expected uptake of Tablo add-ons, including good early demand for our TabloCart new product accessory. More broadly, we see an acute care environment that is much more favorable relative to last year. While hospital nursing shortages continue to affect our acute customers, we've observed stabilization in staffing over the past several quarters, and Q1 was no different. Additionally, programs like Bridge have been successful in helping our commercial team address staffing concerns upfront and early, which continues to prove helpful to our sales process. I'll now turn to our progress in the home, which represents another very large market opportunity for Outset. Our strategy entails growing the number of home programs offering Tablo while simultaneously working to drive the patient census in each program higher than historical standards. Key to both planks of this strategy is maintaining our industry-leading retention rate, which we believe is a central benefit of Tablo and a primary driver for further profitable expansion in this market segment. Specifically for 2023, our home goals include landing the majority of the largest Mid-size Dialysis Operators known as MDOs, initiating home programs with two of the top national IDNs. During the quarter, we made good progress against these goals, including establishing a new relationship with another of the top MDOs and first-time shipments to several other regional home providers. As we land relationships with new providers, we remain equally focused on the expand part of our strategy by deepening our penetration in existing accounts. For example, during the quarter, we increased the number of home programs that have a Tablo home census of more than 10 patients. While the number of these larger programs is still relatively small, we are encouraged by the early indicators that Tablo can significantly increase the number of home hemo patients per program. During the quarter, I was again able to spend time with patients dialyzing at home on Tablo. One visit struck me in particular for a couple of reasons. First, this individual was in her mid 70s and spoke of how easy and effortless it was for her to master Tablo. Our internal data continues to support that Tablo mastery is not defined by age. The patient I visited began dialyzing in-center, but quickly realized how much more freedom and flexibility home dialysis would afford. However, her dialysis clinic provider didn't offer Tablo, so this patient chose to switch clinics and switch physicians in order to access it. While it's still early, we are beginning to see examples of patients who learn about Tablo and are very willing to switch physicians and clinic providers to be able to dialyze on it. Our recent home progress was validated from a clinical perspective at last month's National Kidney Foundation Spring Clinical Meeting, where 5 new abstracts were presented that highlighted a range of clinical and financial benefits of home hemodialysis with Tablo. For example, one study estimated the five year savings for a Medicare Advantage plan generated by prioritizing Tablo home hemodialysis versus in-center hemodialysis. The study found that a Medicare Advantage plan with 500 dialysis members could drive $4.2 million in estimated savings over five years. Another study modeled the monthly per member cost for a health system assuming risk for a dialysis population from a Medicare Advantage plan and the five year savings from establishing a home dialysis program. The study determined that a health system assuming full risk on Medicare Advantage dialysis members could generate $10.7 million in estimated savings over five years. We're proud of data like this and look forward to continuing to build Tablo's clinical evidence base over time. In short, we continue to see growing demand for Tablo at home, fueled by shorter training times, exceptional clinical outcomes, overwhelmingly positive patient experiences, and a differentiated retention rate. Our team also continues to make solid progress operationally, which has resulted in consistent gross margin expansion and enabled us to deliver non-GAAP gross margin of 20.3% in Q1, more than five percentage points over our Q1 2022 gross margin. The first quarter represented our eighth consecutive quarter of increasing gross margins as we move toward our next mile marker of 50% gross margin. Our drivers of margin expansion remain unchanged, and our performance over the last eight quarters illustrates our ability to capture this margin expansion opportunity. From a product innovation standpoint, we are very pleased with demand for TabloCart, a new product accessory we introduced in Q3 of last year that provides additional maneuverability around the hospital and incremental water prefiltration capabilities. TabloCart is sold separately at a gross margin accretive ASP and is proving to be a valuable solution to many of our acute care customers. Finally, I'd like to provide an update on our Tablo cartridge insourcing initiative that we touched on during our last update in February. To date, cartridge production at OMM has progressed very well against our initial expectations, and we're very pleased with the throughput and quality we're seeing. Cartridge insourcing remains an important lever of gross margin improvement over the longer term, and we look forward to providing future updates in quarters ahead as production continues to ramp. Speaking of our operations in Mexico, we were very proud this past quarter to hear that OMM was recognized as a Great Place To Work for 2022, scoring an 88 out of 100 points in its first survey. We believe these results reflect the rewarding, inclusive, and merit-based environment our team has worked hard to cultivate, and it's one of the reasons our employee retention rate at OMM is consistently among the highest compared to similar companies in the area. In summary, our momentum and performance through the first quarter reinforces the conviction I have in our mission and the high confidence I have in our ability to meaningfully grow both near term and long term. We have a differentiated technology in Tablo that every quarter gains even wider recognition for the clinical, operational, and financial benefits it can provide. We are encouraged by our progress across both of our end markets, as well as the continued stability in the macro environment. We're at the front end of penetrating very large and growing end markets. We are confident in our ability to execute through the balance of the year and believe we are very well-positioned to capitalize on the many tailwinds supporting our business and fueling Tablo adoption. With that, I will now turn the call over to Nabeel to review our financials and provide more detail on our expectations and key drivers for the remainder of 2023. Thanks, Leslie. Hello, everyone. Our first quarter revenue increased approximately 4.6% sequentially and 9.5% year-over-year to $33.5 million, exceeding our expectations. The year-over-year change was driven by both higher product revenue and higher service and other revenue. The ongoing increase in recurring consumables and service revenues is one of the benefits of our expanded install base and continues to be one of the key drivers of gross margin expansion. Product revenue was up 5.4% from the prior quarter, despite some expected capital equipment purchasing seasonality, and increased 8.2% year-over-year to $27.8 million. Console revenue grew 2.7% from the fourth quarter and increased by 4.5% year-over-year to $18.9 million. We saw console ASP increase year-over-year, driven primarily by our disciplined approach to pricing and ongoing demand for Tablo accessories. Consumable revenue was $8.9 million, up 11.4% from the prior quarter and an increase of 17.1% versus the prior year as our install base grows. Treatment revenue and cartridge utilization performed well and in line with our expectations. We saw invoice treatments in the acute setting between four and five treatments per week and just above three in the home setting, reflecting the mix of mature consoles and newly shipped consoles that are ramping up. Service and other revenue of $5.7 million was up 0.8% from the prior quarter and higher by 16.4% compared to the prior year. Our core service and other revenue increased approximately 65% year-over-year with the growth of our install base and was offset by the planned expiry of the HHS agreements. As a reminder, the third quarter of 2022 saw the expiry of the final components of our HHS agreements. Moving to gross margin and operating expenses, I will highlight our non-GAAP results. I encourage you to review the reconciliation of GAAP to non-GAAP measures, which can be found in today's earnings release. Our first quarter gross margin was 20.3%, a sequential improvement of 315 basis points and an improvement of just above 5 percentage points versus the prior year period. Service margin declined in the quarter due to investments we made in people and programs designed to drive service efficiency. With these investments made, we expect service margin to improve sequentially through the rest of the year. As Leslie pointed out, this progress marks eight consecutive quarters of consistent and substantial gross margin expansion and once again demonstrates our commitment to reaching our next milestone of 50% gross margin. Primary drivers of margin expansion in the quarter were higher ASPs and lower freight costs. Additionally, margins have, and we expect will continue to, benefit from our ongoing console cost down program and our initiative to insource cartridge production at our facility in Mexico. Our internally manufactured cartridges have now started to reach customers, and we anticipate that by the end of the year, most of the cartridges produced will come from our factory. Operating expenses in the first quarter were $41.7 million, up $5.7 million versus the prior year period. The drivers of OpEx were in our commercial organization in support of our higher revenue and gross margin and in R&D in support of our innovation-driven roadmap. G&A also increased year-over-year as we have the full year impact of investments we made in 2022. We reported first quarter GAAP net loss of $44 million, resulting in a net loss of $0.90 per share compared to a net loss of $36.9 million or $0.78 per share for the prior year period. Non-GAAP net loss was $35.4 million or $0.72 per share compared to a non-GAAP net loss of $31.9 million or $0.67 per share for the same period in 2022. We ended the quarter with approximately $252.5 million in cash equivalents, restricted cash and investments, which includes $100 million of borrowings under our term loan. We continue to have access to up to an additional $200 million of capital under our SLR debt facilities. We burned $38 million during Q1, which we expect to be the highest cash use quarter this year. Moving now to our full year 2023 outlook, starting with revenue. Given our strong performance in the first quarter and the visibility afforded by our backlog and pipeline, we have increased confidence in our ability to execute in 2023. As a result, we are raising our expected 2023 revenue guidance. We now project revenue for the full year to range from $144 million to $150 million, a $4 million increase at the lower end of our prior range of $140 million-$150 million. This updated range represents approximately 25%-30% growth over fiscal year 2022 revenue. Moving to gross margin. Our strong first quarter results give us increased conviction in the gross margin goals we outlined at the beginning of the year. We are raising our gross margin guidance, which we now expect to be in the low 20% range for the full year 2023, up from the approximately 20% that we shared with you on our last call. We have even greater confidence in our expectation that we will exit the fourth quarter in the mid-20% range. Finally, on OpEx. We continue to expect OpEx growth for the full year to be significantly lower than our rate of revenue growth, with OpEx growth in the low double-digit percentage zone. This combination of operating leverage and our commitment to manage working capital efficiently means that we continue to expect that we will burn less cash in 2023 than we did in 2022. In summary, we are very pleased with our momentum starting this year. Tablo continues to demonstrate its economic, clinical and operational value across both acute and home end markets, and our focus on gross margin continues to pay dividends. We're looking forward to executing through the rest of the year. With that, I think we're ready for Q&A. Operator, please open the lines. Thank you very much. At this time, we will conduct the question-and-answer session. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A. Our first question comes from the line of Rick Wise from Stifel. Your line is now open. Good afternoon, Leslie. Hi, Nabeel. Thanks for the question. Let me start off with the guidance. It's great to see, you know, a solid start to the year, and you won't be shocked that, we always want more. Apologies for that with the guide. You all are very thoughtful about providing guidance. Help us maybe think through. I know you don't give quarterly guidance, but help us think through how the quarterly flow is likely to occur. Last year, you know, we saw a step down in the second quarter, but we saw steady sequential improvement each quarter. This year, I'd started the year thinking that we'd see steady sequential increase each quarter. Because of the outperformance and the way you raised the low end and not the high end, it sort of implies maybe flat sequential growth to second quarter and maybe looking back at past years, the $1 million or $2 million sequential increase in each quarter thereafter. I know, and apologize for this long opening statement to the jury, how do we think about it, to, you know, get in the right place to think about hitting that midpoint guidance? Thank you. Yeah. Thanks. Good, good to hear your voice, Rick. Maybe I'll share some thoughts and hear from Nabeel if there's anything to add. I think, well, first and foremost, we too were really pleased with the overperformance and the strong growth that we saw in Q1 and that the strength in the business allowed us to raise the midpoint of the range, now to reflect, you know, 25%-30% growth. I'll say a couple things. First and foremost, while we do have an increased confidence in our ability to execute to the 2023 plan that we outlined at the beginning of the year as a result of the strong Q1, at the same time, I'm always mindful of the fact that it is early in the year, right? We're reporting on about 90 days into 365. I think as always, we're gonna stay focused on executing against a really strong pipeline and taking advantage of the momentum that we did create coming out of these first 90 days. Net-net, I feel really good. I think we all feel really good about how we kicked off the year and excited by our growth opportunity, both near term and long term. Kind of getting to the second part of your question around, you know, kind of shape of the curve. I think you hit the nail on the head, steady sequential improvement each quarter. You know, we don't necessarily see any sort of flatness to it. I think we called out at the beginning of the year, which you noted, that we did expect to see this steady sequential growth rate improvement throughout calendar year, and we don't see that any differently today. Okay. I appreciate some of the extra color and detail I feel like you're giving us this quarter. Maybe just turning to the home program, maybe you can give us even a little more color, if I could be greedy. You know, I'm not sure. I'm looking for some granularity that just helps us, you know, better gauge the kind of progress you're making. Can you give us any color on how many new programs were established, and the kind of increased patient utilization you're seeing in some of your more mature patient, more mature home programs? Just trying to get a sense of the momentum. It sounds like momentum is building and looking for ways to ask that question. Yes, absolutely. You're never greedy, Rick, so you never have to worry about that. Yeah, maybe I'll comment on those in sort of reverse order. On the what are we seeing in terms of the number of home patients per program, and this is perhaps the one thing I am the most kind of encouraged by and bullish about. I think one of the challenges of the past on some of the incumbent home hemo devices is that these home programs would start with, you know, some of the earlier home devices and just kind of linger and never really exceed, you know, 1, 2, 3 patients per program. That has been the history in the home hemo space for quite some time. That so far has not been our experience. Again, I wanna caveat this very clearly. It is early. We're working off of a small base. I acknowledge all of that. What gives me a lot of confidence about the art of, I'll call it the art of the possible here, and the reason why I believe we will have lots of programs over time with 10 plus, and I don't even know what the ceiling is yet, which is great. You know, is the ceiling 20? Could it be 30? I mean, we do have programs, Rick, that are well in excess of 10. I'll tell you that. I just don't wanna be overly promotional about it, in consideration that it is early and it's a small base. I like what I'm seeing. What we continue to see are faster, fast training times regardless of age, regardless of race, regardless of their home status or their education or their income. It's very consistent. Patients finding it accessible and not intimidating, and hearing a lot about nurses and physicians seeing patients choose Tablo when they give them the choice and of course, the longer retention rate. Again, it's early in a small base, but I mean, I've launched a lot of medical devices in my career, and I'm seeing all the signs of potential for adoption here over time that is very robust and much, much higher than we've seen per program with the incumbent device. Those are my perspectives on that one. Then in terms of, I think the first part of your question was about maybe a little bit more color on new home programs. This was an important metric for us last year, which we did meet. Of course, expanding channel access, a different way to say home program remains important to us this year as well. We want the maximum number of home programs to be offering Tablo. That's pretty clear. I think in this past quarter, I was encouraged by seeing growth on all three of the following dimensions. I wanna see growth in the number of new customers. In our scripted remarks, we talked about new customers. Two, I wanna see growth in the number of expansion sites among current customers, i.e to current home providers start to open up new locations that are offering Tablo? Yes, we saw good growth there. I wanna see growth in the number of patients to depth per program. As I just talked about, we saw good growth there. I feel very encouraged across all three dimensions. I really appreciate it. Thanks, Leslie. Thank you. Sure. Please hold for a moment while we compile the roster. Our next question comes from Travis Steed from BofA Securities. Your line is open. Hi, everybody. Congrats on the quarter. Maybe digging a little deeper on Q1 and expectations for the full year. I know coming into the quarter you're expecting capital to be soft in Q1 with seasonality and then accelerate over the year. Curious what you saw on the capital side and expectations for the year? On the utilization, you'd expected to see utilization come in at the lower end, kind of curious the updates on that as well? Yeah. Hey, Travis. It's Nabeel. With respect to Q1, you know, we did see some of the expected capital equipment purchasing seasonality that we talked about on our last call. Travis, you know, we have always talked from a performance perspective. We really have three things in any quarter where we can overperform on, if you will, one is the number of consoles, second is sort of the treatment volume, and third is ASP. In Q1, we saw strong demand for Tablo as we expected. We saw strong treatment performance, I'll talk about utilization in a minute. ASP was where we really shone. We saw stronger ASP, both as a result of the disciplined pricing that we've always been able to maintain. 2, we saw really good mix from the uptake of our accessories, the 24-hour Software treatment and our TabloCart, right? That's kind of from a Q1 perspective, played as we expected with some nice ASP upside. Now on utilization, Travis, you know, we look at utilization in two ways. One, we have our consoles that are cloud-connected. Most of our consoles are cloud-connected. For the consoles that are more mature, that have been in service, we are seeing utilization, actual treatment utilization right in line with kind of 5 treatments per week per console in the acute and 3.5 in the home. With respect to invoice utilization or what we shipped in the quarter, you know, we have grown our installed base pretty significantly over the last few quarters. We're seeing as these new consoles ramp up, what we're seeing is invoice utilization between four and five in the acute setting and a little over three in the home. All right in line with our expectations. That's super helpful. Then maybe, Nabeel, on margins a bit, the gross margin outperformance this quarter. You gave a little color in prepared remarks, but digging a little bit more on the outperformance this quarter and some of the levers that you could pull this year to maybe even get closer to 30% gross margin for the year, you know, if that is even a possible place to get to. Then on OpEx, I heard the comments on low double digits on for this year. Is that the right way to think about it longer term? Is that the kind of leverage we should expect on the operating side, low double-digit OpEx growth kind of long term? Yeah. Travis, on gross margins, number one, this was our eighth consecutive quarter of gross margin expansion, which we are thrilled with. Sort of for margins, we have long had three primary levers, all of which continue to work for us have worked for us and we expect will continue to work for us. One is our active console cost down program. Two is the treatment pull-through. Again, I talked about having a sort of good strength in our treatment. Three is service leverage. Those continue. You know, service, I talked about some of the investments we've made, but sort of those continue. The other thing that gave us benefit in the quarter was the strong ASP that I talked about in response to your last question, right? Our focus for margins, Travis, are they're unchanged. We continue to expect sequential margin expansion. We expect to get margins exiting the year in the mid-20% zone. That's what we are laser focused on. It's all the same things that we've been doing that we're gonna continue to do and drive margins to this mid-20% zone. Travis, that's not obviously that's only a mile marker on our journey to 50%, right? Good news, same thing we've done before. Now on OpEx, the thing I would tell you for OpEx is that we are committed to driving operating leverage. In 2023, OpEx is gonna grow low double-digit percentage on a revenue growth of 25%-30%, and that theme of driving operating leverage will continue as we move forward in time. I don't wanna give guidance on what OpEx may or may not grow at for any period beyond 2023, but what I'll tell you is that we're very focused on operating leverage and very focused on our cash burn. Great. Thanks. Thanks a lot. Thank you for your question. Our next question comes from Shagun Singh from RBC Capital Markets. Your line is open. Great. Thank you so much for taking the question. I was a little intrigued that you added about 30 new hospitals and you called out that it's the largest quarterly growth in new sites since 2021. You know, can you just elaborate on what drove that? More importantly, you know, do you expect that momentum to continue as customers get more familiar with Tablo, and they realize the cost savings? Or is it more, you know, one-off, this quarter? You know, your guidance increase at the midpoint appears to just factor in the Q1 beat and not an improved outlook for the balance of the year. You know, just if you can elaborate there, that would be great. Perhaps even touch on staffing. I think some of our checks were suggesting that it continues to be challenging. Just what you're seeing there would be great. Thank you. Yeah, sure. Maybe I'll jump in on that one. I think the, again, in reverse order, I am noticing a pattern here. In reverse order, I think from our vantage point, again, this is just what we're seeing here on the ground. The macro environment has absolutely improved. Are we back pre-COVID, shiny happy people back in 2017, 2018? No. We have absolutely not seen staffing get any worse. What we're hearing from our hospital customers and even reading some of their prints recently, we continue to hear is that the availability of nursing labor, particularly let's call dialysis nursing labor, because that's what we're talking about here that's relevant for us, is improved and that wages are coming down. I think as we entered the year and thought about our guidance for 2023, we assumed that we would see stabilized staffing because we had started to see it stabilize towards the Q3 and Q4 time period of 2022. Hopefully, so far so good, and it looks like we may have forecasted that correctly to be stable through the year. Now on the 30 new hospitals, I think you were curious about, hey, was this kind of a one-off or is this a durable sign of things to come? I will say I think it's a durable sign of things to come, and I'll tell you why I believe that. You know, cost reduction is an evergreen area of interest for hospitals. You know, as I said in my prepared remarks, perhaps never more so than today. I don't think I've ever talked to a hospital executive who's not interested in improving their operating margins. Again, because dialysis winds up getting delivered as part of hundreds and hundreds of DRGs, it can have an outsized impact on a hospital's P&L if they can save a lot of money there. I think what we're seeing in the 30 new and by the way, let me make a side comment. What I also really liked about Q1 was that in the 30 new, that is a mix of both new customers and existing customers who, because of their results around cost reduction, chose to expand their insourcing programs to new facilities in their networks. That is all tied into Tablo's ability to reduce OpEx and enhance operating efficiencies. Those are durable solutions to unfortunately, a problem that I think is gonna be a durable one as well for health systems. That's really helpful. Sure. Shagun, just a quick thing on guidance. I mean, look, we had a really, really strong Q1 performance. Our business executed really well as we talked about early. And we certainly did what we wanted to do. Having said all that, it's still early. We did raise our guidance range to 25%-30%, reflecting the incremental visibility we have through the rest of the year. We still have three quarters of execution ahead of us. We're very excited about this execution. We have the backlog and the pipeline we need to go and get through this guidance range. It is only Q1. We wanted to sort of be thoughtful in our guidance strategy. Got it. You know, just to follow up on gross margins. You know, you expect to deliver in the low 20s for the full year. Where do you think you might exit 2023? You know, the magnitude of increase in 2023, is that a good proxy of how we should think about 2024? Thank you for taking the question. For sure, Shagun. We expect to exit this year with gross margins in the mid-20% zone, so Q4 gross margin in the mid-20% zone. If you look at our progress, we have delivered now 8 quarters of sequential and steady margin expansion. That trend we would expect to continue to play in the long run, in the medium run, through at least this 50% gross margin mile marker. You know, the levers of margin expansion for us, it's the same 3. It's console cost down, service leverage, consumable pull-through, all of which lend themselves to linear margin expansion as we've done in the past. Thank you. Thank you very much. Our next question comes from Suraj Kalia with Oppenheimer. Suraj, your line is open. Good afternoon, Leslie and Nabeel. Can you hear me all right? Yes. Perfect. Hey, I'll let either one of you tackle this. Nabeel, in your prepared remarks, you mentioned console growth. Consoles were up 2.7% year-over-year. Just wanted to make sure I got that right. Suraj, yes. Console revenue was up 2.7% from the fourth quarter and up 4.5% year-over-year. 4.5. Nabeel, can you split that us to the next layer, i.e., what was the impact of pricing within consoles, if at all? And also how did that split up between home and acute? Suraj. A couple of things. One, as you know, we print our installed base annually, which we did entering 2023, and we will exiting this year. What I'll tell you is that the number of consoles we placed was right in line with our expectation, in line with kind of our commentary around capital equipment purchasing seasonality. We did see higher ASP, as we talked about on the call, which kind of helped us from a margin perspective as well. With respect to acute and home, Suraj, both of our businesses performed exactly as we would expect. They're both very well set up for us to execute on our goals for this full year and will help us grow into our 25%-30% guidance range for the year. Thanks. Next question, please. Thank you. Our next question comes from Josh Jennings with TD Cowen. Your line is open. Hi, good afternoon. Thanks for taking the questions. I was hoping to just follow up on a discussion we had with a hospital executive that had adopted Tablo and insourced their inpatient dialysis service line. It seems as if the competition, DaVita and Fresenius mostly, are having a tough time with increased expenses and offering their hospital customers just a kinda no bargaining power, but jacking up the costs for them to run the inpatient dialysis service line. Is that still ongoing, that dynamic where there are many hospitals that are kind of being held ransom to take up their expenses? How big of an opportunity do you think that is? What inning of that opportunity in terms of the competitors having some issues, do you think you're in right now? Hi, Josh. Yeah, let me, let me think about that a little bit. I wanna give a clever answer on the inning, but it's not coming to me right now. It feels like an opportunity for a witty retort, but I don't have it. Because I, I don't know, obviously, not being inside those organizations and, and knowing what their strategic plans look like. What I can tell you is we did, of course, we did see some of the, the moves, and the behavior that the health systems and hospitals started to experience with their outsourced providers in 2022. That continued through the end of this year. We did certainly contemplate that as we set up guidance for the remainder of the year. Our guidance for 23 did assume that, yes, hospitals and health systems, some of them would continue to experience either elevated pricing or a reduction in service level, or both, or in some cases, the hospitals have had their outsourced agreements terminated on them unexpectedly. I would not say that any of those actions are driving the uptake of Tablo. It does occur, the hospital that you're speaking about is one of them. But by and large, the insourcing of dialysis with Tablo is really considered by the majority of the hospitals to be a strategic cost reduction initiative, regardless of what's going on with their outsourced provider. Hospitals, I think, are ready to control their own destiny, not only from a cost perspective, but as a, as a reminder, some of these other benefits are very real and very valuable. When you own your own dialysis, you control your destiny with regard to compliance. The Joint Commission, very frequently, I've had health systems tell me it's one of their top three citations from Joint Commission, is where are all the maintenance records on your dialysis machine? You take control of your destiny around compliance, you take control of your destiny around length of stay. If you own your own dialysis and it's being done by your own team members, your patients are not in the ICU or on the floor waiting hours and hours and hours for an outsourced vendor to come in and provide it for you. I think there are so many benefits, operational benefits in addition to the cost reduction that are driving the hospitals toward the insourcing solution, regardless of whatever behavior they might be experiencing with their outsourced vendor. Thanks for that. That was a very eloquent answer to an ineloquent question, but that's very helpful to understand those dynamics. Wanted to also ask about just hospitals and hospital systems that are adopting Tablo, retaking control of their inpatient dialysis service line, or just bringing Tablo in to swap out their dialysis systems and already controlling their inpatient dialysis service line. Then considering developing a home program. I just wanted to better understand, I guess, the revenue opportunity and the, I guess the return for these hospitals and hospital systems for bringing that kind of home patients under the roof or recouping them. I'm sure there's many elements, including a halo effect of potentially capturing those patients for all of their care, not just their home dialysis. I wanted to just better understand that dynamic and how attractive it is for hospitals, hospital systems to kind of tack on this home service line as well. Thank you. Of course. Yeah, sure. I'd love to talk about that. I would say a little bit of the what's changed, in terms of the motivation of a health system to start a home program, actually, it has been enhanced because early on, the motivation was a top-line revenue, a new chronic revenue stream, very predictable, very stable, very complementary, you know, frankly, to maybe a less predictable, procedural revenue stream inpatient. That still remains true and is attractive. What has changed, though, and been added is, now it's a solution for a problem. The problem that I've been hearing, a growing number of health system executives talk about is we don't have anywhere to discharge our inpatients out into the community because of these dialysis clinic closures that have been talked about, you know, publicly by many of the clinic operators. These hospitals increasingly are seeing extended length of stay, needing to keep patients in the hospital just to dialyze them for longer and longer because there literally are no chairs available in the community. Clinics are closing and clinics that are not closing, some of them are just reducing their service days or times, which is exacerbating the challenge. I think the reason why we're hearing more and more health system executives talking about standing up home programs, being very, very interested in engaging in the discussion is because it is actually solving an acute (no pun intended) but an acute problem, and it's offering a long-term revenue upside. The long-term revenue upside, which is what you originally asked me about, is in a couple of different components. Of course, you've got per treatment revenue. You also have training revenue. Physicians have billing revenue that they take advantage of. The real advantage for the health system is their lack of overhead. If a hospital is gonna start their own home program, it takes, you know, very little facility space. It does not take, it doesn't take a village. It does not take very many staff members to stand this up. There are variable expenses, but they're variable. I think that the margin contribution, which you also asked me about for the hospital, is really attractive and pretty significant because they're not burdened by the weight of big time overhead. I think for all of those reasons, we are seeing a lot of traction now from the health system. Appreciate it. Thank you, Leslie. Thank you for your question. Our next question comes from Drew Ranieri from Morgan Stanley. Your line is open. Hi, Leslie and Nabeel. Thanks for taking the questions. Just maybe to piggyback off Josh's question that he last asked. As we've talked to nephrologists over since covering the company, I mean, there's been kind of an increasing sense of urgency in the specialty that the care paradigm just needs to change. There's been kind of elevated staffing shortage issues, I think compounding that issue. The mortality issue aside for a second that's happening in dialysis, are you seeing customers being a little bit more front-footed in preparing for what's to come as more dialysis patients are eventually gonna come back into back into the funnel? Just one of the comments that you said earlier, Leslie, was just you're seeing early green shoots of patients really starting to push the decision. How is that going to kind of factor into the next couple years for the company as there's more of a push from patients versus nephrologists? Just love to hear your thoughts on that. Sure. Absolutely. Yes, I think that the feedback that you've received from nephrologists about maybe an increasing urgency to change the care paradigm, is very, very true. In fact, I was talking to a nephrologist yesterday who made the exact same remark to me out of frustration, that he was lacking optionality at this point about finding chairs in the clinic. I do think that that is a tailwind not only for hospitals to kind of, again, think about starting these home programs, but also for nephrologists. I think I do think that a sea change is coming. Of course, change, big change occurs over time. I do think it's coming and this is just another pressure point pushing us to that moment around the staffing shortages, which I don't anticipate will abate in the dialysis clinics anytime soon. In terms of the health system perspective and do I think that they are more front-footed? I not only think it, I see it. Just in terms of the cumulative number of conversations that our team is now having with health systems that wanna look at a full enterprise solution, as we call it, you know, using Tablo from the ICU all the way to home. We are having many more conversations than we had, let's say, this time last year, about deploying a home program in tandem with an acute program. That, again, is being driven, yes, the upside revenue opportunity is great and appreciating it, but it's really about kind of solving a near-term problem around length of stay and discharge. Yeah, I think it is causing health systems to be much more open-minded minimally. I do think they're trying to be a little bit more front-footed, as you put it. Lastly, on the patients and the early green shoots there, that's the right way to characterize it. Again, I don't wanna over-promote, I don't wanna overstate. I have we have evidence that there are an increasing number, while small, and it's a small base, there are an increasing number of patients, perhaps also, you know, influenced by COVID. We've talked about this in the past, that they also view home as an increasingly appreciated safe haven, if you will. Seeing more and more people willing to do the research on their own, activate and advocate for themselves. If that takes switching clinics, we have many examples now of patients who have switched clinics, and also switched physicians in order to be able to access it. I do think it will be a factor for us, Drew, over the next couple of years. I'm interested in this phenomenon because our DTC spend right now is de minimis. We've done a little bit of, I'll call it experimentation/piloting with very, very low cost geotargeted social media, which has produced some good results. We're not even spending money and we're, and we're seeing this movement. I feel, yeah, I feel pretty bullish over the next couple of years, as patients take matters into their own hands. Really helpful. Thank you. Maybe just a last question on innovation. Yeah. You've launched TabloCart. Just maybe talk to us about what's next on the innovation side. Is it hardware? Is it software? As you're thinking about developing products, commercializing them, is there more of an emphasis on monetizing these, like TabloCart, or is it more going to be about maintaining kind of a higher retention rate or stickiness with customers? Just any thoughts there on how you're thinking about future development. Thank you so much. Yeah, sure. Of course. The answer may be all of the above, right? I'll tell you what I think we feel really particularly interested and excited about. We've made some, again, some baby steps to kind of prove to ourselves and our sales team that we can sell, I'll call it core Tablo, and that we can successfully sell add-ons. I think this commercial team has proved so far that we can be really, really good at that. In some cases, these add-ons, it could be hardware. I mean, TabloCart is an example of that. I think I would predict more of the examples of these add-ons for which we will assign very margin friendly margin accretive AFPs to all of them. You will likely see coming out of the software side, both in terms of new features, functions. You may see us also offering premium versions of the Tablo ecosystem because, you know, the Tablo ecosystem is not just the Tablo console, that's only where it starts. Once somebody buys into the ecosystem, they're also buying access to all of the data that flows to and out of Tablo. They're buying access to data analytics and dashboards. They're buying access to EMR integration. There might be, you know, basic versions of that, premium versions of that. And I am very confident that we have a commercial team that can be exceptional in really selling value around not only the console but the ecosystem over time. That's generally the direction I'll see us go. Thanks for taking the questions. Of course. Thank you for your questions. Now we'd like to turn it back to Leslie Trigg for closing remarks. Thanks, thank you all for joining the call today. I really wanna thank the entire Outset team for creating such a strong start to the year. If I see it, the depth of talent and commitment and urgency and intensity that you all display every day is to me second to none in this industry, I could not be prouder of what we continue to achieve together with very forward-leaning, innovation-centered provider partners and clinicians and, most importantly, patients. Lastly, to our shareholders, thank you for your continued support. I really look forward to capitalizing on our early momentum and delivering on our promises through the remainder of the year. Have a great evening, thanks again. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.